Last reviewed · How we verify
LAIV
LAIV, developed by the University of North Carolina, Chapel Hill, is a marketed drug with an unknown mechanism of action. The key composition patent for LAIV is set to expire in 2028, which may provide a period of market exclusivity. The primary risk is the lack of a defined mechanism of action, which could limit further development and regulatory support.
At a glance
| Generic name | LAIV |
|---|---|
| Also known as | FluMist, FluMist® |
| Sponsor | University of North Carolina, Chapel Hill |
| Modality | Biologic |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Revealing Protective Immunity to Influenza Using Systems Immunology (PHASE4)
- Vaccine Pandemic Preparedness Through Airway Immunology Characterization (EARLY_PHASE1)
- Responses to Live Attenuated Influenza Virus (LAIV) in Chronic Obstructive Pulmonary Disease (COPD) (EARLY_PHASE1)
- Live Attenuated Influenza Vaccine as a Nasal Model for Influenza Infection (PHASE4)
- Bacterial Composition and Immune Responses in the Nose and Oropharynx During Influenza Infection (PHASE1)
- Intranasal LAIV Mucosal Immunity Examination (PHASE4)
- The Dynamics of the Immune Responses to Repeat Influenza Vaccination Exposures (DRIVE III) Study (PHASE4)
- Mucosal and Systemic Immune Responses Induced by an Intranasal Influenza Live Attenuated Vaccine (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LAIV CI brief — competitive landscape report
- LAIV updates RSS · CI watch RSS
- University of North Carolina, Chapel Hill portfolio CI